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Background: Mesenchymal stem cells (MSCs) have emerged as a promising candidate for tissue regeneration and restoration of
intra-articular structures such as cartilage, ligaments, and menisci. However, the routine use of MSCs is limited in part by their low
numbers and the need for methods and procedures outside of the joint or surgical field.
Purpose: To demonstrate feasibility of a technique in which minimally manipulated synovial MSCs can be mobilized during knee
arthroscopy, thereby showing proof of concept for the future evaluation and clinical use of native joint resident MSCs in single-
stage joint repair strategies.
Study Design: Descriptive laboratory study.
Methods: Patients (n = 15) undergoing knee arthroscopy who were free from synovitis or active inflammation were selected.
Three samples of irrigation fluid were collected from each patient at inception of the procedure, after an initial inspection of
the joint, and after agitation of the synovium. MSC numbers were evaluated by colony forming unit–fibroblastic assay. The phe-
notype of synovial fluid resident and synovial-mobilized MSCs was determined by flow cytometry, and their functionality was
determined by trilineage differentiation. Adhesion of culture-expanded mobilized MSCs to fibrin scaffolds was also evaluated
to ascertain whether mobilized MSCs might concentrate at sites of bleeding.
Results: Normal irrigation during arthroscopy depleted resident synovial fluid MSCs (4-fold decrease, n = 15). Numbers of MSCs
mobilized through use of a purpose-made device were significantly higher (105-fold) than those mobilized through use of a cytol-
ogy brush (median of 5763 and 54 colonies, respectively; P = .001; n = 15). The mobilized cellular fraction contained viable MSCs
with proliferative potential and trilineage differentiation capacity for bone, cartilage, and fat lineages, and cultured daughter cells
exhibited the standard MSC phenotype. Following culture, mobilized synovial MSCs also adhered to various fibrin scaffolds in
vitro. The technique was simple and convenient to use and was not associated with any complications.
Conclusion: Numbers of functional MSCs can be greatly increased during arthroscopy through use of this technique to mobilize
cells from the synovium.
Clinical Relevance: This study highlights a novel, single-stage technique to increase joint-specific, synovial-derived MSCs and
thereby increase the repair potential of the joint. This technique can be undertaken during many arthroscopic procedures, and it
supports the principle of integrating mobilized MSCs into microfracture sites and sites of bleeding or targeted repair through use
of fibrin-based and other scaffolds.
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Articular cartilage is essential for synovial joint function,
providing a low-friction surface to allow joint movement.
The repair of cartilage, however, is limited given its avas-
cular, aneural, and alymphatic nature. Consequently,
management of isolated articular cartilage defects poses
numerous challenges, and these defects, if left untreated,
are risk factors for developing osteoarthritis (OA) in later
life.9 For more advanced stages of OA, management of
the disease comes at a high global and socioeconomic bur-
den secondary to the effects of disability, comorbid disease,
and expense of treatment.5 As such, more effective, earlier
treatments are needed.
Advanced treatment of cartilage defects is available in
the form of autologous chondrocyte implantation (ACI).
However, ACI is a 2-stage procedure; the first stage requir-
ing harvesting of healthy tissue followed by tissue process-
ing and cellular expansion outside of the surgical field, and
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the second stage entails reimplantation into the defect site.
However, long-term follow-up results of ACI are no better
than those of microfracture, a more conservative, much
less expensive, single-stage procedure.6,23 Mesenchymal
stem cells (MSCs) have been proposed as an alternative
source of reparative cell owing to their ease of harvest
and their proliferative and differentiation capacity.36,37
MSCs are multipotent and are internationally recognized
by their characteristic adherence to plastic; colony-forming
capacity; expression of cell surface markers CD73, CD90,
and CD105; lack of expression of CD14, CD34, CD45, and
HLA-DR; and ability to differentiate in vitro into osteo-
blasts, chondrocytes, and adipocytes.10 Several clinical
studies using MSCs to treat OA24,25,34,43,44,46 have shown
positive results; however, similar to ACI, many MSC meth-
ods incorporate tissue or cell extraction (from either bone
marrow or adipose tissue) before culture expansion and
reimplantation. Intra-articular injection of culture-
expanded MSCs has also been hampered by both cost
and loss of potency.21,40 Other strategies being explored
include the combination of various techniques such as
scaffolds and fibrin glue for implantation and retention
at sites of injury, which appeared promising at second-
look arthroscopy.21,22,45
A major drawback with the aforementioned strategies
involving cellular therapy is the need for more than one
operative procedure. Recent single-stage strategies for
joint repair include the use of adipose tissue stromal vascu-
lar fraction, which contains MSCs.35 However, for single-
stage cartilage repair and OA, joint cavity MSCs including
synovium and synovial fluid (SF) are of particular interest
as these populations of MSCs have superior chondrogenic
capacity and may be more readily and conveniently manip-
ulated since they are already in the surgical field.30,32,39 It
is now recognized that the knee joint cavity has compara-
tively abundant reservoirs of MSCs,30 and such MSCs
might play a role in joint homeostasis and repair. These
MSCs are naturally shed from the synovium20 and are ele-
vated with joint injury and early OA,18,41 but their repair
capacity may be limited due to interactions with SF hya-
luronan that limit their adhesion to cartilage.4 Current
arthroscopic procedures may inadvertently remove these
cells (via saline irrigation), and procedures such as micro-
fracture to encourage MSCs to percolate from the bone
marrow may be inefficient as a result of low and variable
numbers of MSCs in bone marrow.13,29
In this study, we hypothesized that arthroscopic proce-
dures likely wash away resident SF-MSCs imbued with
reparative potential (Figure 1). Our principle aim was to
report the feasibility of a technique that entails a simple, sin-
gle-stage procedure whereby MSCs are dislodged (mobilized)
from the synovium, thereby increasing numbers of joint cav-
ity MSCs with access to cartilage and potentially increasing
the reparative potential of the joint during a range of arthro-
scopic procedures. We sought to determine whether these
synovial-mobilized MSCs (Sm-MSCs) would preserve their
in vitro MSC phenotype and function. Finally, we asked
whether Sm-MSCs would rapidly adhere to blood clots and
fibrin scaffolds (in vitro) as a surrogate for what could happen
in vivo after microfracture or use of a fibrin glue.
METHODS
Patient Recruitment
Patients included in the study were treated arthroscopically
for a spectrum of knee conditions (Table 1) including liga-
ment, meniscal, and cartilage injury, reflecting the varied
nature of current practice and procedures that may warrant
stem cell treatment. The average age of recruited patients
was 32 years, ranging between 18 and 53 (n = 15). At the
time of arthroscopy, patients were free from joint effusion,
synovitis, or active inflammation as determined during
arthroscopy. Ethical approval for this study was granted by
the UK Research Ethics Council, and all study participants
were recruited after providing informed written consent.
Retrieval of MSCs From Irrigation Fluid
Normal saline was used to inflate the knee joint to ade-
quately visualize all joint compartments. To achieve this,
gravity-fed saline was irrigated through the capsule to
maintain a sufficient intra-articular pressure to obtain
arthroscopic views. Irrigation fluid was collected from
each patient at 3 stages during knee arthroscopy. The first
sample contained resident SF-MSCs and was collected by
aspirating the initial saline used to irrigate the joint cavity
(5-50 mL collected; mean, 38 mL). A second sample of fluid
was then collected after inspection of the knee compart-
ments to evaluate the extent to which native SF-MSCs
were being ‘‘washed away’’ during surgery (25-50 mL col-
lected; mean, 39 mL). This sample was collected before
any procedure that breached the subchondral bone, in set-
tings where this was undertaken. Each sample was placed
into a sterile container before transport to the laboratory.
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Mobilization of Synovial MSCs
The feasibility of mobilizing MSCs from the synovium during
arthroscopy was investigated by collecting a third sample of
irrigation fluid after agitation of the synovium to mobilize
MSCs. To do this we used a cytology brush (Figure 2C) rou-
tinely used for diagnostic purposes to sample cells from
mucosal surfaces through natural orifices. Before the induc-
tion of the cytology brush, saline irrigation was stopped, leav-
ing sufficient saline to distend the joint cavity. The cytology
brush (length, 180 mm; diameter of nylon bristled brush
head, 7 mm) (Medical Wires and Equipment Ltd) was then
introduced into the joint through the medial portal, under
arthroscopic guidance, and the synovial surface of the medial
gutter was agitated using the bristled portion for 1 minute.
Mobilized cells were collected by opening the outflow valve
of the arthroscope. Samples (n = 7; 50-70 mL; mean,
53 mL) were collected in a sterile container before transpor-
tation to the laboratory.
The cytology brush was difficult to introduce into the
knee portal due to its inherent flexibility and was limited
in the range of synovium that could be agitated. To further
improve the capability to mobilize synovial MSCs, we used
a purpose-made device fabricated from medical-grade ace-
tal copolymer, the stem cell mobilizing device (STEM
device) (Figure 2, D and E). Similar to the cytology brush,
this optimized device was sterile, was intended for single-
use, and was introduced through the medial knee portal.
The STEM device was tailored for arthroscopic use with
a stiffer arm and blunted end to aid insertion and to limit
potential inadvertent damage to other joint structures. The
design also allowed the STEM device to be guided into the
Figure 1. A proposed use of the technique to mobilize syno-
vial mesenchymal stem cells (MSCs) and supplement carti-
lage healing. (A, B) Joint irrigation replaces synovial fluid
(SF), leading to a loss of resident SF-MSCs while inflating
the knee. (C, D) The stem cell mobilizing device (STEM
device) is introduced into the joint cavity and maneuvered
into the suprapatellar pouch where it physically dislodges
cells, including MSCs, from the synovial lining. (E) These
MSCs are released into the cavity, where they may supple-
ment those from the bone marrow and participate in repair
at sites such as cartilage defects via adhesion to the clot
after microfracture.
TABLE 1
Study Participant (n = 15)
Characteristics and Arthroscopic Procedure
Age, y Sex Surgery
25.4 F Lateral meniscal tear repair
39.0 M Anterior cruciate ligament reconstruction
18.1 M Lateral meniscal tear repair and anterior
cruciate ligament reconstruction
19.3 M Lateral meniscal tear repair
19.9 F Lateral partial meniscal tear repair
52.0 M Medial partial meniscal tear repair
29.5 M Anterior cruciate ligament reconstruction
41.3 M Medial osteochondral fragment and medical
meniscal tear repaira
26.2 M Medial meniscal tear repair and anterior
cruciate ligament reconstructiona
45.3 F Medial chondroplastya
27.1 M Medial chondroplastya
22.0 M Partial lateral meniscal tear repaira
53.7 M Medial chondroplasty and medical meniscal tear
repaira
25.4 M Anterior cruciate ligament reconstruction and
medial meniscal tear repaira
40.3 M Lateral collateral ligament rupture repaira
aDenotes participants undergoing mesenchymal stem cell mobi-
lization with the stem cell mobilizing device (STEM device).
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suprapatellar pouch, where a larger area of fibrous syno-
vium could be agitated to maximize MSC mobilization.
As described above, cells were mobilized by agitating the
bristled portion on the synovial surface for 1 minute. Cells
were retrieved by irrigation and aspiration of saline from
the joint (n = 8; 50-70 mL; mean, 53 mL).
Retrospective Clinical Follow-up
Clinical data for all patients receiving synovial agitation
via the STEM device were evaluated retrospectively by
a senior soft tissue knee fellow (A.A.T.). At the time, this
fellow had completed training and had passed the FRCS
examination. The surgeon gave his opinion regarding the
likely effect that mobilizing MSCs would have on the
expected progression of each participant for his or her
indicated procedure (Table 1). Clinical follow-up duration
ranged from 6 weeks to 1 year.
In Vitro Growth and Quantification
of MSC Colony Number
Colony forming unit–fibroblastic (CFU-F) assays were
used to determine the number of viable MSCs in each
Figure 2. Numbers of mesenchymal stem cells (MSCs) can be increased during arthroscopy by agitation of the synovium. (A) MSC
colony number declines during arthroscopy due to loss of resident cells after saline irrigation (n = 15, horizontal bars represent
medians). (B) MSC colony numbers can be recovered after mobilization from the synovium by use of a standard cytology brush (hor-
izontal bars represent medians, n = 7) (below, example of representative colony forming unit–fibroblastic [CFU-F] dishes). (C) Compar-
ison of the head design and abrasive surfaces of the cytology brush and the purpose-made stem cell mobilizing device (STEM device).
The rigidity of the STEM device, the bullet-shaped nose, and placement of the projections enable easier insertion into the knee through
the soft tissues. (D) Comparison of the length and overall design between the cytology brush and the STEM device (C and D to scale).
The increased length and angled head allowed for the STEM device to be maneuvered into the suprapatellar pouch. (E) MSC colony
number is greatly increased after use of the STEM device during arthroscopy (horizontal bars represent medians, n = 8) (below, exam-
ple of representative CFU-F dishes). (F) Colony numbers are significantly increased (.100-fold) by use of the STEM device compared
with the cytology brush (n = 15) (below, example of representative CFU-F dishes). ns, nonsignificant.
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sample. In brief, samples of joint irrigate were centrifuged
to pellet cells before resuspending in 10 mL of StemMACS
expansion media (Miltenyi Biotec). Duplicate 100 mm–
diameter dishes (containing 2 mL of the cell suspension)
for each sample were cultured for 14 days in StemMACS
expansion medium with twice-weekly media changes,
before both dishes were fixed in 3.7% formalin and stained
with 1% methylene blue (Sigma-Aldrich). All colonies con-
taining more than 50 cells (verified under a microscope)
were counted. The remaining sample was either expanded
for further assays or frozen. For expansion, cells were cul-
tured in StemMACS expansion medium with twice-weekly
media changes until cells reached approximately 90% con-
fluency before being passaged. MSCs were expanded for 3
or 4 passages, all cells were incubated at 37C and 5% CO2.
Immunophenotype of MSCs
Flow cytometry was performed on matched, culture-
expanded SF-MSCs and Sm-MSCs (n = 3 donors) using
a standard panel of markers to define cultured MSCs10
through use of an LSRII 4-laser flow cytometer (BD Bioscien-
ces). The following antibodies and appropriate isotype con-
trols were used: anti-CD34-allophycocyanin-cyanine (APC),
anti-CD19-phycoerythrin (PE), anti-CD45-phycoerythrin-
cyaine (PE-Cy7), anti-CD14-fluorescein isothiocyanate (FITC),
anti-CD73-PE, anti-CD90-PE-Cy7, and anti-CD105-PE (all
from BD Biosciences). Dead cells were discriminated by use
of 4#,6-diamidino-2-phenylindole (DAPI; Sigma-Aldrich). At
least 10,000 live cell events were collected for each antibody
combination.
Trilineage Differentiation of MSCs
Trilineage differentiation of donor-matched, culture-
expanded SF-MSCs and Sm-MSCs (n = 5 donors) was
performed by use of standard protocols.2,17,19,36 Osteogenic
differentiation was assessed with alkaline phosphatase
and Alizarin red staining on days 14 and 21 of culture,
respectively. The medium used for osteogenic differ-
entiation contained Dulbecco’s modified eagle medium
(DMEM) and 100 mg/mL penicillin-streptomycin (Gibco);
10% fetal calf serum (FCS) (Biosera); and 100 nM dexa-
methasone, 10 mM b-glycerolphosphate, and 50 mM ascor-
bic acid (all from Sigma-Aldrich). Quantitative analysis of
calcium deposition was performed on day 21 according to
the manufacturer’s instructions (calcium assay; Senitial
Diagnostics). Adipogenic differentiation was assessed
with Oil Red-O staining and quantified using Nile red fluo-
rescence on day 21 of culture. The medium used for adipo-
genic differentiation contained DMEM and 100 mg/mL
penicillin-streptomycin (Gibco); 10% FCS (Biosera); 10%
horse serum (Stem Cell Technologies); and 500 mM hydro-
cortisone, 500 mM isobutylmethylxanthine, and 60 mM
indomethacin (all from Sigma-Aldrich). Pellet cultures
were used to evaluate chondrogenesis on day 21 of culture;
the medium contained high-glucose DMEM supplemented
with 100 mg/mL penicillin-streptomycin and 100 mg/mL
sodium pyruvate, 40 mg/mL L-proline, 50 mg/mL L-ascorbic
acid 2-phosphate, 1.25 mg/mL bovine serum albumin,
ITS1 (a 13mixture of recombinant human insulin, human
transferrin, and sodium selenite), 100 nM dexamethasone,
and 10 ng/mL recombinant human transforming growth
factor-b3 (all from Sigma-Aldrich). For quantitative analy-
sis, glycosaminoglycan production was measured according
to the manufacturer’s instructions (Blyscan assay; Bio-
color). Toluidine blue staining was used for qualitative
analysis of frozen sections.
MSC Adhesion to Biological Scaffolds
Culture-expanded Sm-MSCs were used to assess their abil-
ity to adhere to various biological scaffolds. Scaffolds were
formed from whole blood (WB), platelet-rich plasma (PRP),
or fibrin glue (FG). Blood from healthy volunteers was col-
lected in sodium citrate tubes. PRP was prepared after cen-
trifugation at 250g for 10 minutes. Platelets were further
concentrated from the supernatant by centrifugation at
1500g for 10 minutes, and the pelleted platelets were
resuspended in one-fifth of their original volume using
donor matched serum. FG scaffolds were formed with
bovine purified fibrinogen (23.7 mg/mL) resuspended in
StemMACS expansion media. All scaffolds including WB
were formed after coagulation by the addition of 100 mM
calcium chloride (CaCL2) and 50 U/mL thrombin (Sigma-
Aldrich). To each scaffold and each time point (in tripli-
cate), 10,000 Sm-MSCs were added and allowed to adhere
for 10, 30, or 60 minutes before the supernatant was
removed and any nonadherent cells were transferred to tis-
sue culture well. These cells were allowed to attach to the
culture well before fixing, staining with 1% methylene
blue, and counting. A standard curve using a known num-
ber of cells was used to interpolate counted cells as a per-
centage of initial cell number.
Statistical Analysis
Due to the limited number of samples, all data were
assumed to be nonparametric. As such, paired samples
were analyzed with Wilcoxon single rank test and non-
paired samples with Mann-Whitney U test. The confidence
level for each was set at 95%. All statistical analysis was
performed with SPSS version 21 (IBM).
RESULTS
Retrieval and Enumeration of MSCs
From Irrigation Fluid
CFU-F numbers (a measure of viable MSCs) varied
between donors (Figure 2A), with MSC colony number sig-
nificantly greater (P = .01, n = 15) in the initial irrigate
(median, 360; range, 1-1675) compared with the second
sample (median, 68; range, 4-885). Samples of subsequent
irrigation fluid indicated that MSC numbers on average
decreased 4-fold over the course of surgery, suggesting
that standard orthopaedic practice depletes the joint of
stem cells.
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Intraoperative Mobilization of MSCs
From the Synovium
Resident SF-MSCs were collected as above, and these
served as a baseline to assess the ability of the cytology
brush to mobilize MSCs from the synovium. The number
of resident SF-MSCs in these donors (n = 7) ranged from
3 to 1235 (Figure 2B). After synovial agitation with the
cytology brush, in comparison with MSC numbers obtained
before synovial mobilization, the MSC colony increased
approximately 5-fold. However, MSC numbers declined
relative to the baseline resident SF population from the
initial irrigate, ranging from 8 to 775. The median number
of colonies formed decreased from 256 in the resident pop-
ulation to 54 after synovial agitation, representing a 3.7-
fold decrease (not significant).
MSCs Are Further Augmented Using
a Purpose Made Device
Intraoperative use of the cytology brush mobilized low
numbers of synovial lining MSCs. This could be attribut-
able to the limited area of synovium that the cytology
brush could access and because this type of device is
intended to trap and remove cells from the body. To over-
come this limitation and to further increase MSC number
during surgery, we used a purpose-made device (the
STEM device; Figure 2, C and D) to ascertain whether
this pool of regenerative cells located in the synovial lining
could be further exploited. In each case (n = 8), the use of
the STEM device reliably and significantly increased the
number of MSCs mobilized intraoperatively over those res-
ident in the SF (Figure 2E). After synovial agitation with
the STEM device, the median number of colonies formed
was 5763 (range, 225-46,500), representing a 10-fold
increase over the matched SF resident population (P =
.007; median, 531; range, 1-1675). In comparison with
the cytology brush, the STEM device mobilized 105-fold
greater viable MSCs from the synovial lining during
arthroscopy (Figure 2F) (P = .001). Finally, we retrospec-
tively examined follow-up clinical data for those patients
who received MSC mobilization with the STEM device.
From these data, none of the patients appeared to fare
worse than would be expected for their primary surgery
had they not undergone MSCmobilization with this device.
Mobilized MSCs Are Phenotypically
and Functionally Comparable to SF-MSCs
To determine whether Sm-MSCs were comparable to their
resident SF counterparts and withstood the biophysical
manipulation, we used standard techniques on culture-
expanded, donor-matched cells to perform immunopheno-
typing and multilineage differentiation. Both SF-MSCs
and Sm-MSCs were positive for standard MSCs surface
markers CD73, CD90, and CD105 and negative for common
hematopoietic lineage markers CD14, CD19, CD45, and
CD34 (Figure 3A), confirming the feasibility of this proce-
dure to mobilize stem cells during the surgical procedure.
Differentiation of Sm-MSCs toward chondrogenic (Fig-
ure 3B), osteogenic (Figure 3C), and adipogenic (Figure
3D) lineages was also compared with donor-matched SF-
MSCs. In each case, qualitative and quantitative assay dem-
onstrated that the differentiation capacities of the mobilized
MSCs were comparable to those of their matched SF coun-
terparts. These data show that Sm-MSCs are comparable
Figure 3. Mobilized mesenchymal stem cells (MSCs) are
indistinguishable from resident synovial fluid (SF)–MSCs. (A)
Resident and mobilized MSCs have a comparable immuno-
phenotype, which is consistent with both SF- and synovium-
derived MSCs (n = 3 matched donors). (B-D) Resident and
mobilized MSCs have comparable trilineage differentiation
capacity as demonstrated by quantitative assays (left, n = 5
matched donors) illustrating their chondrogenic, osteogenic,
and adipogenic potential, respectively, and qualitative assays
(right, representative matched donors).
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to SF-MSCs, consistent with previous literature describing
synovium as a source of intra-articular MSCs.39
Mobilized MSCs Rapidly Adhere
to Biological Scaffolds
Finally, having shown how MSC numbers can be reliably
increased intraoperatively from the joint synovium and
that Sm-MSCs fulfill the requirement of an MSC, we
sought to determine whether these cells could be targeted
to sites of interest via adhesion to relevant biological scaf-
folds. In these experiments, the ability of mobilized MSCs
to adhere to FG, PRP, or WB clots was evaluated in vitro.
Sm-MSCs from a single donor began to adhere to the sur-
face of all 3 scaffolds within 5 minutes (Figure 4A). By 60
minutes, 89.7% (66.5%), 88.3% (63.5%), and 84.0%
(68.3%) of Sm-MSCs had adhered to the FG, PRP, and
WB clots, respectively. To test donor variability, Sm-
MSCs from 3 donors were allowed to adhere to FG
scaffolds alone (Figure 4B). Sm-MSCs adhered rapidly,
with little variation between donors. After 60 minutes,
83.5% (62.6%), 96.7% (61.0%), and 86.1% (63.1%) of
Sm-MSCs from each donor were adhered to FG scaffold.
DISCUSSION
Better cartilage and joint repair strategies are increasingly
needed, and MSCs show great promise. To fully exploit these
cells, new strategies and methods that limit operative time,
cost, and tissue manipulation are required. Emerging data
from several randomized controlled trials indicate that
MSC therapy shows promise, at least in the short term.31,48
However, the majority of trials so far have used culture-
expanded MSCs from bone marrow or adipose tissue or other
ex vivo manipulation strategies. Here we provide proof of
concept that minimally manipulated MSCs within the syno-
vium can be easily mobilized and their numbers greatly aug-
mented in a simple, single-stage procedure as part of knee
arthroscopy. Furthermore, since these MSCs are derived
from the synovium, which is the most potent source of chon-
drogenic progenitors, this technique has promising potential
to increase the reparative capacity of the knee.39
The discovery of joint resident MSCs highlights potential
new avenues to explore in the treatment of knee intra-
articular pathologies.30 Studies have shown that numbers of
MSCs in SF increase in patients with OA and cartilage
injury18,19,41 and after ligament and meniscal damage.28,33
However, joint irrigation during arthroscopy, which aids visu-
alization of the joint and removes debris, also removes SF
with the potentially undesirable effect of reducing numbers
of SF-MSCs.12 SF-MSCs are thought to derive from the syno-
vium owing to their superior clonogenic and chondrogenic
potential and shared gene expression profiles.3,39,41 The syno-
vium itself holds great potential in providing an abundant
endogenous supply of joint-specific MSCs; synovial MSCs
are found at a frequency of ~1%, 500 times more numerous
than in bone marrow.10,13,17,39,43 Additionally, the synovium,
cartilage, and other joint structures share a common
progenitor that is distinct from that of bone tissue,26,27 sug-
gesting that the synovium harbors a joint tissue–specific
stem cell population.15,30,38 The remarkable cartilage repair
seen in patients with OA who are treated with knee joint dis-
traction is testament to the intrinsic regenerative potential of
these joint resident cells.42 In these patients, significant areas
of denuded bone are replaced by intrinsic cartilage repair
activity, providing functional and clinical benefits.14,42,47 It is
thought that the temporarily altered biochemical and biome-
chanical environment created by joint distraction favors
endogenous joint resident MSC activity and is in part respon-
sible for this intrinsic repair where no extrinsic growth fac-
tors, scaffolds, or MSCs have been introduced.4
Synovial MSCs have already been used clinically with
promising results; however, these studies also required
Figure 4. Mobilized mesenchymal stem cells (MSCs) rapidly
adhere to a range of biological scaffolds. (A) Mobilized MSCs
from a single donor show a rapid ability to adhere to a range
of relevant biological scaffolds such as platelet-rich plasma
and whole blood clots as well as fibrin glue. (B) Mobilized
MSCs from multiple donors all exhibit the same rapid adhe-
sion to a fibrin glue scaffold (n = 3).
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a 2-stage procedure and in vitro culture expansion.1,40 The
purpose of the current study was therefore to demonstrate
proof of concept for a new, single-stage procedure to
increase stem cell numbers in the joint, thereby avoiding
ex vivo manipulation of tissue and cells. Furthermore,
our data show that the Sm-MSCs rapidly adhere to biolog-
ical scaffolds such as FG, PRP, and WB clots, thus demon-
strating relevance in the context of existing procedures
such as microfracture (Figure 1) or future practical appli-
cations with fibrin-based scaffolds.
Characterization of Sm-MSCs showed consistent pheno-
type and trilineage differentiation with their donor-matched
SF counterparts, effectively demonstrating successful mobi-
lization of joint resident MSCs. In the context of arthro-
scopic surgery, where saline inflation and irrigation of the
joint result in the loss of SF-MSCs, this technique (when
performed with the STEM device) increases the number
and availability of stem cells (compared with those resident
before and during arthroscopy); further, if left in the joint,
these cells occupy a more suitable biochemical environment,
being free from high-molecular-weight hyaluronan, which
can limit their interaction with cartilage.4 Depending on
the arthroscopic procedure used, Sm-MSCs could be aspi-
rated from the joint for loading onto a scaffold or entrapped
in the joint as a final-stage procedure.
One of the concerns of stem cell–based cartilage repair is
cartilage hypertrophy, which leads to uneven articular sur-
face. Synovium-derived MSCs exhibit superior chondrogenic
capacity with limited potential to hypertrophy compared
with MSCs derived from adipose and bone marrow.15 Our
results using the STEM device are encouraging, supporting
the potential of this technique and the synovium as a robust
and convenient source of MSCs. Although colony numbers
expressed here are low in comparison with the number of
chondrocytes or MSCs currently used in the clinical setting,
these Sm-MSCs have lost none of their proliferative or differ-
entiation capacity as a result of culture expansion.7,16 Direct
comparisons between these colony numbers and those
obtained from fresh bone marrow aspirate are difficult owing
to variations in aspiration technique. However, when an opti-
mized aspiration procedure is used, in which small draw vol-
umes are taken from multiple sites, this would be equivalent
to up to 80 mL of bone marrow.8,13 For nonoptimized bone
marrow aspirates in which larger volumes (~60 mL) are
drawn before being concentrated,11 we can equate the num-
ber of colonies mobilized with the STEM device as being
equivalent to up to 380 mL. More research and clinical stud-
ies are required to determine whether these Sm-MSCs will
lead to clinically significant results. However, the idea is to
achieve cartilage repair with a single procedure and thus
avoid the need for 2-stage harvest and cell expansion. This
will in turn reduce the burden and risks to the patient and
the cost to the health care provider.
Limitations
We recognize that synovial MSC mobilization was performed
on a limited number of patients with a range of injuries. These
injuries and the time between injury and surgery may affect
the numbers of MSCs and the ability to mobilize them into
the joint cavity. The primary purpose of the study was to
determine to what extent synovial MSCs could be mobilized
during a range of routine arthroscopies. In this study, the
stem cells were removed from the joint for laboratory analysis,
and so there was no expected benefit to the patient.
CONCLUSION
Here we show proof of concept that a potent source of joint-
specific mesenchymal stem cells can be accessed and those
cells can be mobilized during routine arthroscopy. This
technique can reliably and rapidly repopulate the knee
with synovial MSCs that are viable, with trilineage poten-
tial in a single-stage procedure. Further studies are needed
to ascertain whether this leads to better joint repair across
the spectrum of arthroscopic procedures for damaged carti-
lage and other joint structures.
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